Global Challenges with Oral Antivirals for COVID-19
Open Access
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in Population Health Management
- Vol. 25 (6), 822-827
- https://doi.org/10.1089/pop.2022.0171
Abstract
Oral antivirals for COVID-19 can be game changers in low- and middle-income countries (LMICs). Challenges that may hinder current and future oral antiviral rollouts span use in special populations, drug–drug and herb–drug interactions, adverse events, development of resistance, black markets, and equity in access and prescribing. Future antivirals may address some of these barriers; however, health systems around the world should be equipped to receive and administer COVID-19 oral antivirals. Improvements in manufacturing capacity, community engagement, capacity for testing and linkage to care, and systems for surveillance and safety monitoring could “change the game” for LMICs, irrespective of any specific antiviral drug. Investments in health care infrastructure can promote resilience, not only for COVID-19 but also for future local and global health crises.Keywords
This publication has 21 references indexed in Scilit:
- Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019Open Forum Infectious Diseases, 2021
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsThe New England Journal of Medicine, 2021
- Fake covid vaccines boost the black market for counterfeit medicinesBMJ, 2021
- A global database of COVID-19 vaccinationsNature Human Behaviour, 2021
- COVID-19 mitigation measures to maintain access to essential health services: new opportunities with long-term benefitsPan African Medical Journal, 2021
- A living WHO guideline on drugs for covid-19BMJ, 2020
- Drug resistance in influenza A virus: the epidemiology and managementInfection and Drug Resistance, 2017
- Oseltamivir Resistance — Disabling Our Influenza DefensesThe New England Journal of Medicine, 2005
- Position statement: global neuraminidase inhibitor susceptibility networkAntiviral Research, 2001
- Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteersBritish Journal of Clinical Pharmacology, 1998